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Summary
(NPAz)2NSOAz ('SOAz') has been the first of a large number of new in-
organic heterocycles to undergo clinical trials. The majority of these com-
pounds, in particular the aziridino substituted agents, display cytotoxic activi-
ty in in vllro systems. A limited number of these have been tested in tumor-
bearing laboratory animals, and activity was confirmed. These findings
generated hope, that one or more of the derivatives might have clinically
useful activity, and clinical studies were initiated. The objective of these in-
vestigations was to provide first experience with one of the agents in ad-
ministration to humans and to obtain pharmacological data that would be
helpful in establishing structure-activity relationships of the heterocyclic
compounds.
In chapter 2, the results of a phase I clinical study in 3l patients are
reported. Treatment took place by IV iniusion of SOAz on four consecutive
days, to be repeated after full hematological recovery had taken place. A total
of 46 courses evaluable for toxicity was given and the tumor response was
evaluable in 2l patients. Seven dose-levels, ranging from 25 mg,/m'? to 300
mg/m'zwere studied with three to six patients at each level. The only major
toxicity was myelosuppression, especially thrombocytopenia, which was
dose-limiting. Platelets decreased from the l4th day on, with a nadir 4 to 5
weeks after administration. In most patients, recovery was complete after 6
to 9 weeks. Myelosuppression was clearly cumulative in subsequent courses
and proved irreversible in two patients. Furthermore, anemia occurred, but
otherwise SOAz was remarkably well tolerated. Patients who had received no
or only minor chemotherapy prior to treatment with SOAz, tolerated up to
300 mglm', heavily pretreated patients tolerated only 175 mg/m'. No objec-
tive responses were observed. Because of cumulation of myelotoxicity and the
risk of irriversible aplasia, phase II studies using this regimen are not
recommended.
In chapter 3 a second phase I trial is reported, that evaluates the feasibility
of a regimen employing weekly administrations. Eleven patients were treated
with doses of 50, 75 or 100 mglm' as a rapid IV infusion once a week. The
treatment was discontinued at the first signs of developing throm-
bocytopenia. Nevertheless, severe myelotoxicity, which was prolonged and
delayed in onset, precluded continuing treatment for more than three courses
in 9 of l l  patients. In two patients thrombocytopenia showed no signs of
recovery 9 and I I weeks after the last infusion. Two minor responses were
observed, but because of the risk of inacceptably prolonged bone marrow
aplasia, this regimen seems equally unsuitable for phase II studies as the one
reported in chapter 2.
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Chapter 4 deals with the development of a sensitive assay for the deter-
mination of SOAz and other inorganic heterocycles in biological fluids. The
method is based on capillary gaschromatography used in conjunction with a
thermionic detector. A structural analogue of SOAz, (NPAz)2NSOPh
('SOPh'),  is used as an internal standard. The detection l imit for SOAz using
this method is 0.01 mgll  for serum and 0.04 mgll  for urine, which makes i t
sufficiently sensitive for the determination of pharmacokinetic parameters in
man.
Chapter 5 presents the results of pharmacokinetic studies in six patients
treated with SOAz. The drug was administered as a rapid IV infusion. Serum
decay curves could be fitted to an open two-compartment model of drug
disappearance. After a short ini t ial  phase with a t172 (t S.D.) of 7.8 + 4.2
minutes, a terminal phase with a dose-independent half life of 203 + l7
minutes occurred. The coefficient of apparent distribution was 0.71 + 0. 13.
The renal clearance was 75 + ll mllmin and the total body clearance 162 1
23 ml,/min. A percentage of 46.5 + 6.6 of the administered drug could be
recovered unchanged in the urine within 24 hours. Since achievable peak
serum concentrations were somewhat lower than concentrations known to be
active in vitro, it is concluded that a regimen employing large single doses may
be advantageous. Dose adjustments should be made for patients with im-
paired renal function.
Chapter 6 touches upon the sensitive issue of informed consent' of
research subjects, a problem which is even more complex in phase I studies
of new antitumor agents than in other research settings. In order to evaluate
the quality of an informed consent procedure, forty-seven patients with ad-
vanced cancer were offered participation in one of the trials. The procedure
consisted of three separate conversations. In the first session, the possible
risks and benefits of a phase I study were informally explained by the pa-
tient's personal physician. The second session was attended by the patient, a
relative or trusted friend, a registered nurse and a physician. The third session
was held at least five days after the second. Forty-one patients gave their con-
sent, motivated by hope for improvement of their conditions, pressure ex-
erted by relatives and friends, the desire to contribute to the progress of
medicine or simply because they felt to have 'no choice'. Encouragement by
relatives or friends seems to be a powerful incentive to participate. A period
of a few days to consult with relatives, friends or trusted physicians seems
helpful in arriving at a well-considered decision.
Although further clinical trials of SOAz cannot be recommended at this
time, several properties of the agent found in the present study, are of poten-
tial interest. The delayed type of myelosuppression and the pronounced
tendency to cumulation of toxici ty in the almost complete absence of ex-
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tramedullary toxicity, strongly suggest hat SOAz is specifically toxic for
human bone marrow stem cells. Experiments in mice in order to establish a
model for this toxicity have yielded encouraging results (Rodenhuis S, Mulder
NH, van de Gampel JC, unpublished).
Evidently, it would be of great importance to develop a screening method,
in order to select other derivatives for clinical studies on the basis of the
absence of this specific roxicity.
